Date of event
Continuing Education Credits
Liver Cancer SIG
- Kathryn Fowler
- Nicole Rich, MD
- Elizabeth Hecht
- Maarouf Hoteit, MD
- Victoria Chernyak, MD
- Anjana Pillai, MD, FAASLD
- Amit Singal, MD, MS, FAASLD
- Claude Sirlin, MD
The webinar will cover various applications of LI-RADS from HCC surveillance to diagnosis. We will hear from expert radiologists and hepatologists about their perspectives on LI-RADS and HCC-related imaging. Learners will hear about rationale behind LI-RADS categories, how this aligns with AASLD guidelines and OPTN policies, and how it can be applied in clinical practice.
Kathryn J. Fowler, MD, FSAR
Kathryn J. Fowler, MD is a Professor for Radiology at University of California San Diego. Dr. Fowler is the Division Chief of Abdominal Imaging, Co-Director of the Liver Imaging Group, Co-PI of the T32 NIH funded research residency. She specializes in liver imaging with MRI and Ultrasound primarily. The Liver Imaging Group research focuses on noninvasive quantitative imaging biomarkers for chronic liver disease, detection of hepatocellular carcinoma, and artificial intelligence-based tools for segmentation and characterization of liver related diseases. She is the lead PI on grants funded by the Department of Defense, National Institution of Health, Foundation for the National Institution of Health, and industry.
Dr. Fowler has more than 180 publications related to imaging of liver and emerging imaging technologies. She has delivered over 100 lectures at national/international forums. Dr. Fowler is involved in societal leadership within the field of radiology as a member of the Steering Committee, co-chair of the Management working group, and co-chair of the Hepatobiliary contrast working group for the American College of Radiology Liver Imaging Reporting and Data System. She is Chair of the American College of Radiology Gastrointestinal Panel for Appropriateness Criteria. She is a Senior Deputy Editor for Radiology. Dr. Fowler serves as the Education Portfolio Director for the Society of Abdominal Radiology.
Maarouf A. Hoteit, MD, AGAF
Maarouf A. Hoteit is an Associate Professor of Clinical Medicine in the division of Gastroenterology and Hepatology at Perelman School of Medicine of the University of Pennsylvania. Dr Hoteit is the director of liver tumor clinic, program director of the transplant hepatology fellowship and medical director of liver transplant at the University of Pennsylvania. His expertise is in primary liver cancer and liver transplantation for malignant disease. He contributed to work related to expanding transplant criteria for HCC, HCC biomarkers and predicting toxicity of liver directed therapy for HCC.
Dr Hoteit is associate editor of Liver Transplantation, a member of the hepatobiliary neoplasia and liver transplantation interest groups, and a member of the annual meeting education committee of the American Association for Study of Liver Disease (AASLD). His key research interest is in advancing the cure of unresectable HCC and other malignant tumors of the liver through transplantation by improving patient selection and neoadjuvant therapy. He contributed to multicenter studies of HCC downstaging that lead to the adoption of downstaging with neoadjuvant therapy as an acceptable pathway to prioritize transplantation by United Network for Organ Sharing (UNOS). He contributes to several early detection and prognostic biomarker studies in HCC. He has an interest in methods to accurately predict toxicity of liver directed therapy (LDT) for HCC and initiated a pilot study evaluating the application of functional liver assays in LDT. He lectures in both the medical school and the dental school at the University of Pennsylvania, and is a key teaching faculty for the medicine residency and GI fellowship programs at Penn, where he received several teaching accolades. In his role as a transplant hepatology fellowship director he mentored several trainees in advanced liver disease and transplantation who hold faculty positions in leading academic programs across the country, and contributed to the efforts to design the new AASLD transplant hepatology fellowship application process.
Victoria Chernyak, MD MS
Victoria Chernyak, MD MS is a Director of Oncological Imaging for Beth Israel Deaconess Medical Center. She is an expert in liver imaging, with special interest in liver cancer diagnosis. She is the current Chair of the LI-RADS Steering Committee, and a member of the AASLD HCC Metrics PMC.
Dr. Chernyak serves as editorial board member for major journals such as Journal of Magnetic Resonance Imaging, European Radiology and Abdominal Imaging. She is currently Chair of the Liver Imaging Reporting and Data System (LI-RADS). She is the co- Principal Investigator for American College of Radiology-sponsored grant establishing clinical and imaging registry for patients with or at risk of hepatocellular carcinoma. As an active teacher and educator, she has mentored over multiple trainees, including college students, medical students, radiology residents and fellows, as well as junior faculty at Assistant/Associate Professor rank from Montefiore Medical Center, BIDMC, and other institutions. She is an author of over 120 peer-reviewed publications, and a co-editor of the LI-RADS v2018 Manual.
Anjana Pillai, MD FAASLD
Anjana Pillai, MD, is an Associate Professor of Medicine at the University of Chicago Medicine and a board-certified gastroenterologist and transplant hepatologist who specializes in the management of chronic liver disease and hepatobiliary malignancies. Dr. Pillai is the medical director of University of Chicago's multidisciplinary liver tumor program, the medical director of the Adult Living Donor Liver Transplant Program and the Program Director for the ACGME accredited Transplant Hepatology Fellowship.
Dr. Pillai is also an active researcher and collaborator with a focus on hepatocellular carcinoma. In 2019, she co-founded the HCC Therapeutics Targets Conference (HCC-TAG), a new national conference that is geared towards bringing clinicians and researchers for a focused interactive update on the most relevant advances and challenges in the diagnosis and therapy of HCC. She also serves on the editorial board for both Hepatology and Liver Transplantation. Within AASLD, she serves on the Practice Guidelines Committee and was recently elected to the Liver Cancer SIG as a Steering Committee Member. She also serves on the AASLD Coagulopathy Expert Panel on peri-procedure bleeding Risk Management in Persons with Cirrhosis and was recently appointed as the AASLD representative to the ACR Committee on Appropriateness Criteria.
Amit G. Singal MD MS FAASLD
Amit G. Singal MD MS FAASLD is a Professor of Medicine for University of Texas Southwestern Medical Center. He serves as Medical Director of the Liver Tumor Program, Chief of Hepatology and Associate Division Chief at UT Southwestern. He is also co-leader of the Population Science and Cancer Control Program at the Simmons Cancer Center. His primary research interest is hepatocellular carcinoma (HCC) prevention, early detection, and treatment. He has over 200 peer-reviewed original publications and has been awarded the Willis C Maddrey Distinguished Chair in Liver Disease, Dedman Family Scholar in Clinical Care, and Blue Faery Award for Excellence in Liver Cancer Research.
Dr. Singal has served as associate editor for journals such as Clinical Gastroenterology and Hepatology, and PLOS Medicine. He is Chair of the Liver Cancer Special Interest Group for the AASLD, member of the Governing Board for the International Liver Cancer Association (ILCA), and member of the LI-RADS Steering Committee. He is the principal investigator for several R01 and U01 grants examining the HCC care continuum, ranging from prevention to screening and early detection to treatment and survivorship. He mentors several residents and fellows and has been awarded the Internal Medicine Outstanding Research Mentor Award three of the past four years.
Claude B. Sirlin, MD
Claude B. Sirlin, MD, Professor of Radiology at UC San Diego in the United States, is a clinician scientist who specializes in liver imaging, metabolic imaging, quantitative imaging, and imaging of abdominal cancers. Dr Sirlin founded and co-directs UC San Diego Health’s Liver Imaging Group, which seeks to advance screening, diagnosis, treatment, and outcomes of individuals with liver disease. He is the Founder of the Liver Imaging Reporting and Data System, which is now used worldwide for radiologic imaging of liver cancer. Dr. Sirlin mentors medical students, residents, fellows, visiting scholars, and junior faculty. One of Dr. Sirlin’s goals is to advance international collaboration and consensus for liver imaging.